Notable Runner: Reata Pharmaceuticals Inc’s Stock Is Sell After Today’s Big Decline

Notable Runner: Reata Pharmaceuticals Inc's Stock Is Sell After Today's Big Decline

The stock of Reata Pharmaceuticals Inc (NASDAQ:RETA) is a huge mover today! About 89,990 shares traded hands or 81.40% up from the average. Reata Pharmaceuticals Inc (NASDAQ:RETA) has risen 6.00% since October 16, 2016 and is uptrending. It has outperformed by 2.07% the S&P500.
The move comes after 5 months negative chart setup for the $840.54 million company. It was reported on Nov, 15 by Barchart.com. We have $31.62 PT which if reached, will make NASDAQ:RETA worth $58.84 million less.

According to Zacks Investment Research, “Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States.”

More notable recent Reata Pharmaceuticals Inc (NASDAQ:RETA) news were published by: Reuters.com which released: “BRIEF-Reata Pharmaceuticals, Inc. announces third quarter 2016 results” on November 14, 2016, also Marketwatch.com with their article: “Reata Pharmaceuticals Inc. Cl A” published on April 03, 2013, Globenewswire.com published: “Reata Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering” on May 26, 2016. More interesting news about Reata Pharmaceuticals Inc (NASDAQ:RETA) were released by: Globenewswire.com and their article: “Reata Pharmaceuticals, Inc. Announces Second Quarter 2016 Financial and …” published on August 11, 2016 as well as Globenewswire.com‘s news article titled: “Reata Pharmaceuticals, Inc. Announces Interim Data From Extension Phase 2 …” with publication date: June 23, 2016.

RETA Company Profile

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Firm is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates, bardoxolone methyl and RTA 408, are members of a class of small molecules called antioxidant inflammation modulators (AIMs).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment